Semaglutide and Longevity: Old Female Mice Lived Longer. What Does That Mean for Us?

Semaglutide has had a rather busy career. It began as a treatment for type 2 diabetes, became a highly effective obesity medicine, reduced cardiovascular and kidney events in selected high-risk patients, and then acquired an unofficial side job as the molecule onto which society projects nearly every wish involving appetite, metabolism, and the inconvenient passage of time. Now comes the headline everyone knew was eventually coming: old mice given semaglutide lived longer.

The new experiment deserves attention because it did something longevity studies often postpone until the sequel. Treatment began late in life, not in young animals raised from birth inside a metabolic monastery. Twenty-month-old female C57BL/6 mice received a daily injection of semaglutide or vehicle. Median survival increased from 742 days in the control group to 834 days in the treated group—92 days, or about 12.4%. The investigators also found better physical performance, cognition, glucose control, stem-cell measures, and molecular signs associated with aging [1]. This is unusually coherent preclinical evidence. It is also evidence from one strain, one sex, and one species. The distance between those two sentences is where most of the responsible interpretation lives.

What the mice actually experienced

The lifespan cohort included 39 control mice and 40 semaglutide-treated mice. Treatment continued until death. A separate cohort was treated for three months so the researchers could examine physiology and tissues without waiting for the actuarial department to finish its work. Semaglutide reduced food intake by 24% and lowered body weight, predominantly by reducing fat. The proportion of lean mass rose, which is not the same as proving that the mice grew additional muscle. That distinction is small enough to disappear in advertising and large enough to matter in geriatric medicine.

After three months, treated mice moved and explored more in unfamiliar environments, performed better on rotarod and inverted-screen tests, ran longer on a treadmill, cleared glucose more effectively, and did better in the Barnes maze, a test of spatial learning and memory. The motor advantages on the rotarod and inverted screen remained significant after body weight was included as a statistical covariate, reducing the possibility that a lighter mouse merely found the apparatus easier [1]. Still, a collection of behavioral tests is not a tiny mouse autobiography. It measures selected functions under laboratory conditions.

A tour through the hallmarks

The researchers then examined several hallmarks of aging—the interlocking processes used to organize modern geroscience, including chronic inflammation, cellular senescence, mitochondrial dysfunction, loss of protein quality control, genomic instability, and stem-cell exhaustion [2]. Semaglutide lowered inflammatory signals and markers of senescence such as p16, p21, and senescence-associated beta-galactosidase. It reduced gamma-H2AX, a marker associated with DNA damage, increased tissue ATP, lowered reactive oxygen species, and softened signs of mitochondrial and endoplasmic-reticulum stress [1].

Blood-forming stem cells showed less of the myeloid bias associated with age, while markers of new neuron formation increased in the hippocampal dentate gyrus. Liver RNA sequencing suggested lower inflammatory and lipid-metabolism programs and stronger adaptive-immune, insulin-response, DNA-repair, and protein-maintenance programs. NAD+ increased, several sirtuins rose, circulating IGF-1 fell, and Oser1—a conserved FOXO-regulated longevity gene—was induced. This is an impressive biological pattern. But pathway enrichment and correlated markers do not establish which change caused longer life. When a house stops leaking after ten repairs, the dry carpet does not identify the decisive nail.

Is this semaglutide, calorie restriction, or both?

Here lies the central interpretive problem. Semaglutide makes animals and people eat less. In a human laboratory study, the drug reduced ad-libitum energy intake, suppressed hunger and cravings, and produced weight loss predominantly from fat [3]. Reduced calorie intake is itself one of the oldest and most reproducible ways to extend lifespan in laboratory animals. The new mouse study therefore compared semaglutide with a group receiving matched 24% calorie restriction. Both interventions produced similar food intake, body-weight loss, and fat loss, and both preserved several functions that declined in controls [1].

The comparison was clever because the animals reached the same calorie reduction by different routes. Calorie-restricted mice devoured their allotment and then fasted for a long interval; semaglutide-treated mice ate more gradually because appetite was suppressed. Semaglutide produced more favorable trajectories than calorie restriction in exploratory behavior, spatial memory, and glucose control, suggesting effects beyond calorie reduction alone [1]. But the matched-calorie experiment followed function for five months; it was not a pair-fed lifespan study. Thus the experiment does not tell us what fraction of those extra 92 median days came from reduced intake, fat loss, direct GLP-1-receptor signaling, or their interaction. Calling the drug a calorie-restriction mimetic is reasonable. Calling it calorie restriction in a syringe is not.

Even in humans, calorie restriction has not supplied a simple answer. In the randomized CALERIE trial, two years of modest calorie restriction slowed one DNA-methylation measure of the pace of aging but did not significantly change two other epigenetic clocks [4]. Biomarkers are useful instruments, not notarized certificates of rejuvenation. Neither calorie restriction nor a drug that imitates parts of it can be promoted from mechanism to human lifespan extension without long, controlled outcome data.

Human evidence is substantial—and answers a different question

Semaglutide already has far more human evidence than the average proposed geroprotector. In STEP 1, 1,961 adults with overweight or obesity but without diabetes were randomized to weekly semaglutide 2.4 mg or placebo, both with lifestyle intervention. At 68 weeks, mean weight change was -14.9% with semaglutide versus -2.4% with placebo. Gastrointestinal symptoms were common, and more participants discontinued treatment because of them [5]. That establishes effective obesity treatment. It does not establish slower aging in healthy-weight older adults.

In SELECT, 17,604 adults aged 45 or older with overweight or obesity and established cardiovascular disease, but no diabetes, had fewer major cardiovascular events with semaglutide: 6.5% versus 8.0% over a mean follow-up of almost 40 months [6]. In FLOW, 3,533 people with type 2 diabetes and chronic kidney disease had fewer major kidney outcomes and cardiovascular deaths; all-cause mortality was also lower during the trial [7]. These results matter enormously. Preventing heart attacks, kidney failure, and premature deaths is part of extending healthy life. Yet a reduction in events among people with serious disease risk is not evidence that semaglutide slows the fundamental aging process or extends maximum human lifespan. A bridge can save commuters without proving it changes the speed of the river.

The missing mice—and the missing humans

All animals in the longevity experiment were female. The investigators chose females partly to avoid aggression and injuries that can confound survival studies in group-housed male mice. That is a defensible design choice, not a biological exemption. We do not know whether males would receive the same benefit, a smaller one, or a different collection of tradeoffs. We also do not know how another mouse strain would respond. Genetic uniformity cleans up an experiment while making the world outside the cage look suspiciously untidy.

Body composition deserves similar caution. The mice lost mainly fat and increased their percentage of lean mass. In people, semaglutide-driven weight loss can include absolute lean-mass loss even when the percentage of lean tissue rises [8]. That may be especially important in older adults already vulnerable to sarcopenia, frailty, or inadequate protein intake. A human trial is investigating semaglutide's effects on physical function, body composition, and aging biomarkers in older adults with overweight and insulin resistance, but the published record is a protocol, not a result [9]. The experiment we most want has therefore been announced, not completed.

The mouse investigators reported no adverse effects within the endpoints they monitored. Human prescribing still involves known gastrointestinal effects and individualized considerations, and the mouse dose and daily injection schedule should not be translated into a do-it-yourself human regimen. The study also disclosed that the University of California filed a patent application covering GLP-1-receptor agonists for healthy aging. That does not invalidate the findings; it does increase the value of independent replication.

A genuinely exciting result, kept in its proper container

The most interesting feature of this study is not merely that semaglutide extended median survival. It is that an intervention begun at an advanced age improved survival together with several domains of function and multiple layers of aging biology. Late-life success is what a practical geroscience treatment would need; most humans are disinclined to begin an eighty-year drug regimen during preschool. The direct calorie-restriction comparison also makes the work more informative than another catalogue of attractive biomarkers.

What comes next is straightforward to describe and difficult to execute: replication in males and genetically diverse animals; lifespan studies that separate reduced food intake from direct drug action; careful measurement of muscle, bone, cognition, cancer, and adverse effects; and randomized trials in older people using validated functional outcomes—not merely a clock that moves in the preferred direction. Until then, semaglutide is a proven medicine for specific metabolic and cardiovascular indications and a compelling candidate for geroscience research. It is not a proven anti-aging prescription. Old female mice have opened the door. Humans have not yet walked through it.

References

[1] Feng Y, Barthez M, Wang Y, et al. Late-life semaglutide treatment slows ageing and extends lifespan in female mice. Nature. Published online September 2, 2026. doi:10.1038/s41586-026-10940-7.

[2] Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023;186(2):243-278. doi:10.1016/j.cell.2022.11.001.

[3] Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242-1251. doi:10.1111/dom.12932.

[4] Waziry R, Ryan CP, Corcoran DL, et al. Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial. Nat Aging. 2023;3(3):248-257. doi:10.1038/s43587-022-00357-y.

[5] Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183.

[6] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563.

[7] Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-121. doi:10.1056/NEJMoa2403347.

[8] McCrimmon RJ, Catarig AM, Frias JP, et al. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia. 2020;63(3):473-485. doi:10.1007/s00125-019-05065-8.

[9] Cortes TM, Vasquez L, Serra MC, et al. Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial. JMIR Res Protoc. 2024;13:e62667. doi:10.2196/62667.